Login / Signup

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.

Marika CinauseroNoemi LaproviteraGiovanna De MaglioLorenzo GerratanaMattia RiefoloMarianna MacerelliMichelangelo FiorentinoElisa PorcelliniVanessa BuoroFrancesco GelsominoAnna SquadrilliGianpiero FasolaMassimo NegriniMarcello TiseoManuela FerracinAndrea Ardizzoni
Published in: Therapeutic advances in medical oncology (2019)
This study suggests that the analysis of KRAS and ERBB-family gene mutational status is valuable when assessing the clinical practice for the selection of NSCLC patients to treat with PD-1 inhibitors.
Keyphrases